Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.1 (
cytosine deaminase
)
747
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to estimate the efficacy of mesenchymal stem cell-based suicide gene therapy in mice bearing murine melanoma B16F10. Adipose mesenchymal stem cells (MSCs) were transfected with plasmid constructs expressing
cytosine deaminase
fused with uracil phosphoribosyltransferase (
CDA
/UPRT) or
CDA
/UPRT fused with HSV-1 tegument protein VP22 (
CDA
/UPRT/VP22). In this study, we demonstrate that direct intratumoral transplantation of MSCs expressing
CDA
/UPRT or
CDA
/UPRT/VP22 followed by systemic administration of 5-fluorocytosine (5-FC) results in a significant inhibition of tumor growth. There was a 53% reduction in tumor volume in mice treated with
CDA
/UPRT-MSCs and 58% reduction in tumor volume in mice treated with
CDA
/UPRT/VP22-MSCs as compared with control animals transplanted with B16F10 melanoma alone. Injection of
CDA
/UPRT-MSC and
CDA
/UPRT/VP22-MSC prolonged the life span of mice bearing B16F10 melanoma by 15 and 26%, respectively. The data indicate that in murine B16F10 melanoma model, MSCs encoding
CDA
/UPRT suicide gene have a significant antitumor effect.
...
PMID:[Mesenchymal stem cells expressing cytosine deaminase inhibit growth of murine melanoma B16F10 in vivo]. 2671 Jul 83
Thyroid cancer is the most common type of malignant endocrine tumor diagnosed. Previous studies have indicated that gene therapy is the most promising and effective therapeutic method for thyroid cancer. Therefore, in the present study, Na
131
I/5-fluorocytosine (5-FC) treatment was combined with
cytosine deaminase
(CD, encoded by the
CDA
gene) and sodium iodide symporter (NIS, encoded by the
SLC5A5
gene) to act together as a therapeutic tool for thyroid cancer. The present study explored the combined cytotoxic effects of adenovirus-mediated CD and NIS under the control of the progression elevated gene-3 (
PEG-3
) promoter (Ad-PEG-3-CD-NIS) with Na
131
I/5-FC against the human thyroid cancer TT cell line
in vitro
. The
PEG-3
fragment was obtained by polymerase chain reaction (PCR) using rat genomic DNA as the template, and then Ad-
PEG-3-
CDA
-SLC5A5
was constructed using
Xba
I. TT cells were transfected by recombinant adenovirus. The method of reverse transcription-quantitative PCR was performed to test the expression of CD and NIS at the level of transcription. The morphological change was assessed by fluorescence microscopy and investigated by western blot analysis. An MTT assay was used to determine the number of living cells inhibited by single or combination therapies on TT cells. The results indicated that the
PEG-3
was successfully cloned, and was also positively regulated in 293 cells.
CDA
and
SLC5A5
genes were highly expressed in TT cells. Na
131
I combined with 5-FC significantly decreased the human thyroid cancer cells. In conclusion, combination therapy of Ad-
PEG3-
CDA
-SLC5A5
and Na
131
I/5-FC induces significantly more apoptotic characteristics than either single treatment with Ad-
PEG-3-
CDA
-SLC5A5
or Na
131
I/5-FC, and low doses of Ad-
PEG-3-
CDA
-SLC5A5
enhanced the cytotoxic effects.
...
PMID:Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na
131
I/5-FC on human thyroid cancer. 2934 84